The $AMRN/Vascepa story...
A sad 🥲
but insightful🤔
story about the value of U.S. biopharma patents
From ~$23/share to ~$1/share
in ~5 yrs
Vascepa - the "good" fatty acid in fish oil
• Approved for 2 indications
⇨ Pts with very high blood trigs
⇨ Cardiovascular risk reduction
• Existing U.S. patents cover Indication 2 and mfg method
📅 Fall 2018
• Vascepa Reduce-It Ph3 cardiovascular risk results
• Landmark cardiovascular risk Study
$$$$AMRN ~$23/share
📅 2020/21
• U.S. Composition patents killed
• Vascepa goes generic in U.S.
• Vascepa approved in EP
⇨ + EP exclusivity & EP comp patents
$$AMRN ~$4.50/share
📅 Q1 2023 Vascepa European sales
• $0.8M
📅 7/28/23
~$140M = Enterprise Value
$AMRN 1.19/share
Lots more patent yada yada
to the AMRN story
Could be called the AMRN patent trap
• Method patent protection
For lead indication
but...
• No composition patent protection
• No FDA exclusivity
• An approved, but unpatented indication
• Generics with "skinny" labels
• Induced vs. direct infringement
Maybe I'll provide a detailed article later🤔
In the meantime...
If you want to read more about the AMRN story
from an investor perspective:
Check out my and BiopharmIQ's AMRN tweet string:
